LUND, SWEDEN – Immunovia AB (publ) ) (“Immunovia”), a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced the build up of the Company’s management team with a new Senior Vice President of Sales NA (North America), Michael Pettigrew.
“We are excited to welcome Michael Pettigrew to our team, as we continue to strengthen and prepare for our third quarter 2020 launch of IMMray™ PanCan-d, Immunovia’s test for early detection of pancreatic cancer,” said Mats Grahn, CEO of Immunovia. “Michael has a very successful track record in product launches and sales growth, couple that with a unique set of leadership skills – he is a perfect fit for Immunovia.”
Michael Pettigrew joins Immunovia from Thermo Fisher Scientific, where he was the Vice President of Americas. He brings over 30 years of experience and has focused his extensive global expertise in the management of marketing & sales, business and strategic account development, licensing, mergers & acquisition, and commercial technology platform development. While he was at Thermo Fisher Scientific, he managed large regional based sales teams (USA, Canada, Latin America, and South America) by providing sales, technical support, and customer support. Prior to Thermo Fisher Scientific, Michael was the Vice President of Corporate Development at Magellan Biosciences, where he was focused on M&A and licensing. Prior to that, Michael held positions at GE Healthcare (Vice President, Sales), Amersham (Vice President, Genomics), and Pharmacia (Director of Marketing, North America).
He received his Bachelor of Science in Biology at Fairleigh Dickinson University.
“This is an exciting time for Immunovia, and I am very pleased to be given the opportunity to lead the North American sales team and grow Immunovia’s business. I am very enthusiastic about Immunovia´s core technology platform, IMMray™, and I look forward to working with the whole Immunovia team to revolutionize early detection of pancreatic cancer and help patients and their families,” commented Michael Pettigrew, Senior Vice President of Sales NA.
For more information, please contact:
Director of Investor Relations
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on January 13, 2020.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.